Your go-to
radiopharmaceutical resource

Radiopharmaceutical development is accelerating. Pipelines are expanding, investment remains strong, and more programs are advancing into later-stage clinical evaluation. Infrastructure is scaling alongside this growth, with new manufacturing facilities, isotope…

Radiopharmaceutical development is accelerating. Pipelines are deeper, investment remains strong, and more programs are advancing into mid- and late-stage clinical evaluation. Against that backdrop, a familiar question has resurfaced across…

Radiopharmaceutical therapy is accelerating. Investment continues to build, new programs are moving through the clinic, and radioligand therapies are beginning to take a more central role in oncology care. In…

Alpha-emitting radiopharmaceuticals have spent decades in the background of nuclear medicine, recognized for their biological power but constrained by practical limitations. That balance is beginning to shift. As isotope production,…

2025 was a defining year for the radiopharmaceutical industry. Innovation accelerated, investment deepened, and clinical development efforts advanced across therapeutic and diagnostic programs. Throughout this momentum, one trend became especially…

Submitting an IND: A Critical Milestone Submitting an Investigational New Drug (IND) application is a pivotal moment for any radiopharmaceutical program. Too often, delays or regulatory holds stem not from…

The FDA’s recent draft guidance for radiopharmaceuticals marks a pivotal moment for the field. For the first time, the agency provided clearer expectations for how these therapies should be developed,…

In radiopharmaceuticals, preclinical success isn’t just about demonstrating activity but building something that can survive contact with reality. That means processes that can scale, compliance strategies that hold up under…

With new isotopes entering clinical trials and therapies showing promise across oncology, the pipeline for radiopharmaceuticals is expanding. Yet even as science accelerates, supply chain vulnerabilities remain one of the…

The road from discovery to commercialization is complex for any therapeutic—but in radiopharmaceuticals, that journey brings an entirely different level of scientific and regulatory intricacy.  Developers working in radiopharmaceuticals often…